NCT06203275View on ClinicalTrials.gov

The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Paroxetine

intervention group n=22 Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus paroxetine 12.5 mg daily

DRUG

Placebo

Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily

All Listed Sponsors

lead

aya ramadan ashmawy sarhan

OTHER